Tonix Pharma, Kansas University Join Forces To Work On Next-Gen mRNA-Based COVID-19 Vaccine


Tonix Pharmaceuticals Holding Corp TNXP has announced an exclusive option agreement and research collaboration with Kansas State University (K-State) to develop zinc nanoparticle (ZNP) mRNA vaccines.

  • The ZNP technology replaces the lipid-nanoparticle (LNP) technology in current COVID-19 vaccines. 
  • Pfizer Inc PFEBioNTech SE BNTX and Moderna Inc MRNA COVID-19 shots are based on the LNP platform.
  • The new ZNP technology can confer increased stability to mRNA vaccines over a wide range of temperatures. 
  • Under the research agreement, K-State will advance the preclinical development of a new ZNP mRNA vaccine to protect against COVID-19 based on the spike protein from SARS-CoV-2.
  • Recently, the FDA signed off Tonix Pharma's Investigational New Drug (IND) application to initiate a human study for TNX-2100, a skin test to measure delayed-type hypersensitivity (DTH) to SARS-CoV-2.
  • Price Action: TNXP shares are up 3.96% at $0.41 during the premarket session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLong IdeasNewsPenny StocksHealth CareContractsMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusCOVID-19 VaccinePreclinical Phase
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!